The Henry M. Jackson Foundation for the Advancement of Military Medicine

Advancing Military Medicine

Search Results - shiv+srivastava

5 Results Sort By:
Prostate Cancer Gene Profiles (HJF 346-13)
Prostate cancer (PCa) has the highest heritability and widest racial disparities of any cancer. African Americans (AAs) in the United States are known to have a higher incidence and mortality for PCa compared to Caucasian Americans (CAs). Researchers at the Henry M. Jackson Foundation (HJF), Uniformed Services University for Health Sciences (USU),...
Published: 6/11/2025   |   Inventor(s): Shiv Srivastava, Albert Dobi, Gyorgy Petrovics, Thomas Werner, Martin Seifert, Matthias Scherf
Keywords(s): African American, Ethnic-Specific Genes, Genome Sequencing, Mortality, Prostate Cancer, Prostate Cancer Incidence
Category(s): Diagnostic
DNA Damage Repair Genes in Prostate Cancer - (HJF 557-19)
Prostate cancer patients with DDRG mutations are increasingly considered for targeted cancer therapies. Currently available DDRG mutation tests rely on a rather small number of genes which are not often mutated in African American prostate cancer patients. This invention describes a robust data set on inherited mutations which can be used to develop...
Published: 6/11/2025   |   Inventor(s): Gyorgy Petrovics, Shiv Srivastava
Keywords(s): African American, Caucasian, DDRG, Mutation, Precision Therapy, Prostate Cancer
Category(s): Diagnostic
ETV1 Monoclonal Antibodies - (HJF 641-23)
ETV1 is a protein of Erythroblast Transformation Specific (ETS) family of transcription factors. Dysregulation of ETV-1 has been observed in many malignancies including, gastrointestinal stromal (GIS), prostatic tumors, and in triple-negative breast cancer. Researchers at HJF and the Uniformed Services University for the Health Sciences (USU) have...
Published: 5/29/2025   |   Inventor(s): Shyh-Han Tan, Albert Dobi, Shiv Srivastava
Keywords(s): ERG, Monoclonal Antibodies, Prostate Cancer
Category(s): Research Tool, Diagnostic
Protein Panels for the Early Diagnosis/Prognosis and Treatment of Aggressive Prostate Cancer - (HJF 528-18)
Prostate cancer is the second most common cancer in men and fourth most common among all cancers. Researchers at HJF in collaboration with researchers at the Pacific Northwest National Laboratory (PNNL) and the National Cancer Institute (NCI) have developed a novel protein-panel based diagnosis or prognosis method that can diagnose and identify if the...
Published: 5/29/2025   |   Inventor(s): Shiv Srivastava, Gyorgy Petrovics, Jennifer Cullen, Tao Liu, Karin Rodland
Keywords(s): Biomarker, Cancer Therapy, Mass Spectrometry (MS), Prostate Cancer, Prostatectomy, Protein Panels, Selected Reaction Monitoring (SRM)
Category(s): Diagnostic
Urine-Based Prostate Cancer Diagnostics - (HJF 485-17)
A technology for screening and diagnosing prostate cancer based on urine exosomes is available for licensing from HJF. Applications and Advantages Screening for and diagnosis prostate cancer with superior accuracy than the standard of care. Convenience of using regular urine sample that can be collected at home, as opposed to post-DRE urine sample. RNA...
Published: 5/2/2025   |   Inventor(s): Shiv Srivastava, Gyorgy Petrovics, Indu Kohaar
Keywords(s): Diagnostics, Prostate Cancer
Category(s): Diagnostic